@article {Aref-Eshghi388, author = {Erfan Aref-Eshghi and Ming Liu and Seyd Babak Razavi-Lopez and Kensuke Hirasawa and Patricia E. Harper and Glynn Martin and Andrew Furey and Roger Green and Guang Sun and Proton Rahman and Guangju Zhai}, title = {SMAD3 Is Upregulated in Human Osteoarthritic Cartilage Independent of the Promoter DNA Methylation}, volume = {43}, number = {2}, pages = {388--394}, year = {2016}, doi = {10.3899/jrheum.150609}, publisher = {The Journal of Rheumatology}, abstract = {Objective. To compare SMAD3 gene expression between human osteoarthritic and healthy cartilage and to examine whether expression is regulated by the promoter DNA methylation of the gene.Methods. Human cartilage samples were collected from patients undergoing total hip/knee joint replacement surgery due to primary osteoarthritis (OA), and from patients with hip fractures as controls. DNA/RNA was extracted from the cartilage tissues. Real-time quantitative PCR was performed to measure gene expression, and Sequenom EpiTyper was used to assay DNA methylation. Mann-Whitney test was used to compare the methylation and expression levels between OA cases and controls. Spearman rank correlation coefficient was calculated to examine the association between the methylation and gene expression.Results. A total of 58 patients with OA (36 women, 22 men; mean age 64 {\textpm} 9 yrs) and 55 controls (43 women, 12 men; mean age 79 {\textpm} 10 yrs) were studied. SMAD3 expression was on average 83\% higher in OA cartilage than in controls (p = 0.0005). No difference was observed for DNA methylation levels in the SMAD3 promoter region between OA cases and controls. No correlation was found between SMAD3 expression and promoter DNA methylation.Conclusion. Our study demonstrates that SMAD3 is significantly overexpressed in OA. This overexpression cannot be explained by DNA methylation in the promoter region. The results suggest that the transforming growth factor-β/SMAD3 pathway may be overactivated in OA cartilage and has potential in developing targeted therapies for OA.}, issn = {0315-162X}, URL = {https://www.jrheum.org/content/43/2/388}, eprint = {https://www.jrheum.org/content/43/2/388.full.pdf}, journal = {The Journal of Rheumatology} }